Clinical Gastroenterology and Hepatology
Volume 10, Issue 1 , Pages 30-36, January 2012

Low Risk of Gastrointestinal Cancer Among Patients With Celiac Disease, Inflammation, or Latent Celiac Disease

  • Peter Elfström

      Affiliations

    • Department of Neonatology, Astrid Lindgren Children's Hospital-Danderyd, Karolinska University Hospital, Stockholm, Sweden
  • ,
  • Fredrik Granath

      Affiliations

    • Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
  • ,
  • Weimin Ye

      Affiliations

    • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
  • ,
  • Jonas F. Ludvigsson

      Affiliations

    • Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    • Department of Pediatrics, Örebro University Hospital, Örebro, Sweden
    • Corresponding Author InformationReprint requests Address requests for reprints to: Jonas F. Ludvigsson, MD, PhD, Department of Pediatrics, Örebro University Hospital, 701 85 Örebro, Sweden. fax: 46-0-19-18-79-15

published online 01 July 2011.

Background & Aims

Celiac disease has been associated with gastrointestinal (GI) cancers in small studies; risks have not been estimated from large populations or based on histopathology analyses.

Methods

We examined the risk of GI cancers by using data from cohorts of patients with celiac disease (villous atrophy, Marsh score of 3; n = 28,882) or inflammation (Marsh score of 1–2; n = 12,860); biopsy samples were evaluated at 28 pathology centers. A third cohort included 3705 individuals with latent celiac disease (normal mucosa, but positive serology results). Data were compared with those from an age- and sex-matched population.

Results

Of patients with celiac disease, 372 developed incident GI cancers; 347 patients with inflammation and 38 with latent celiac disease developed GI cancers. In the first year after diagnosis and initial biopsy, celiac disease was associated with 5.95-fold increase in risk of incident GI cancer (95% confidence interval [CI], 4.64–7.64); the hazard ratio [HR] for inflammation was 9.13 (95% CI, 7.19–11.6) and for latent celiac disease was 8.10 (95% CI, 4.69–14.0). After the first year, patients were at no significant increase in risk for GI cancers; the HR for celiac disease was 1.07 (95% CI, 0.93–1.23), for inflammation it was 1.16 (95% CI, 0.98–1.37), and for latent celiac disease it was 0.96 (95% CI, 0.56–1.66). The absolute risk for any GI cancer in patients with celiac disease was 101/100,000 person-years, with an excess risk of 2/100,000 person-years.

Conclusions

Although celiac disease, inflammation, and latent disease all increase risk for GI cancers in the first year after diagnosis, there is no increase in risk thereafter.

Keywords:  Autoimmune Disorder , Malignancy , Cancer Incidence , Epidemiology

Abbreviations used in this paper:  AGA, anti-gliadin antibodies, BMI, body mass index, CD, celiac disease, CI, confidence interval, EMA, endomysial antibody, GI, gastrointestinal, HR, hazard ratio, Ig, immunoglobulin, TTG, tissue transglutaminase, VA, villous atrophy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Watch this article's video abstract and others at http://tiny.cc/bz9jv.

 Conflicts of interest The authors disclose no conflicts.

 Funding This project was supported by grants from the Örebro University Hospital Research Foundation, Örebro University, Swedish Society of Medicine, the Swedish Research Council, the Sven Jerring Foundation, the Örebro Society of Medicine, the Karolinska Institutet, the Clas Groschinsky Foundation, the Juhlin Foundation, the Majblomman Foundation, the Uppsala-Örebro Regional Research Council, and the Swedish Celiac Society.

PII: S1542-3565(11)00670-7

doi:10.1016/j.cgh.2011.06.029

Clinical Gastroenterology and Hepatology
Volume 10, Issue 1 , Pages 30-36, January 2012